Fezolinetant and Elinzanetant Therapy for Menopausal Women Experiencing Vasomotor Symptoms

血管舒缩 医学 科克伦图书馆 安慰剂 随机对照试验 更年期 荟萃分析 平均差 内科学 体质指数 置信区间 替代医学 病理
作者
Artur Menegaz de Almeida,Paloma Oliveira,Lucca Moreira Lopes,Marianna Leite,Victória Morbach,Francinny Alves Kelly,Ismael Barros,Francisco Cézar Aquino de Moraes,Alexandra Secreti Prevedello
出处
期刊:Obstetrics & Gynecology [Lippincott Williams & Wilkins]
被引量:4
标识
DOI:10.1097/aog.0000000000005812
摘要

OBJECTIVE: To assess the efficacy and safety of fezolinetant and elinzanetant for vasomotor symptoms in menopausal women. DATA SOURCES: MEDLINE, EMBASE, and Cochrane databases were systematically searched until August 22, 2024. Because the Cochrane Library included all the identified randomized controlled trials (RCTs), it was unnecessary to search ClinicalTrials.gov. The following words made up the search strategy, which was applied to the three databases: fezolinetant, elinzanetant, vasomotor symptoms, and menopause. METHODS OF STUDY SELECTION: Only RCTs comparing fezolinetant and elinzanetant with placebo for vasomotor symptoms in menopausal women were included. TABULATION, INTEGRATION, AND RESULTS: We extracted the number of patients, mean age, body mass index (BMI), and number of patients who underwent oophorectomy. Data were examined with the Mantel–Haenszel method and 95% CIs. Heterogeneity was assessed with I 2 statistics. R 4.3.2 was used for statistical analysis. Seven RCTs with 4,087 patients were included in the analysis. Fezolinetant and elinzanetant were associated with diminished vasomotor symptom frequency: fezolinetant 30 mg (mean difference 2.16, 95% CI, 1.54–2.79, I 2 =0%), fezolinetant 45 mg (mean difference 2.54, 95% CI, 1.86–3.21, I 2 =0%), and elinzanetant 120 mg (mean difference 2.99, 95% CI, 1.74–4.23, I 2 =0%). Both drugs also showed a decrease in vasomotor symptom severity: fezolinetant 30 mg (mean difference 0.20, 95% CI, 0.09–0.33, I 2 =0%), fezolinetant 45 mg (mean difference 0.24, 95% CI, 0.13–0.34, I 2 =0%), and elinzanetant 120 mg (mean difference 0.36, 95% CI, 0.26–0.46, I 2 =0%). Elinzanetant 120 mg showed a significant improvement in sleep quality (mean difference 4.65, 95% CI, 3.73–5.56, I 2 =0%). Elinzanetant 120 mg was associated with the occurrence of drug-related adverse events (11.70% vs 20.75%, risk ratio [RR] 0.57, 95% CI, 0.39–0.82, I 2 =19%) and headache (2.54% vs 8.0%, RR 0.32, 95% CI, 0.16–0.64, I 2 =0%). CONCLUSION: In this meta-analysis, consistent results suggest that fezolinetant and elinzanetant are associated with beneficial outcomes in menopausal women with vasomotor symptoms. Elinzanetant provided a larger effect size in vasomotor symptom frequency and severity reduction and greatly improved sleep quality compared with fezolinetant. SYSTEMATIC REVIEW REGISTRATION: PROSPERO, CRD42023469952.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
6秒前
hellokitty完成签到,获得积分10
9秒前
9秒前
小四发布了新的文献求助10
10秒前
16秒前
西瓜完成签到 ,获得积分10
16秒前
包容的忆灵完成签到 ,获得积分10
19秒前
高兴尔冬发布了新的文献求助10
21秒前
xiang完成签到 ,获得积分0
24秒前
小四完成签到,获得积分10
27秒前
FashionBoy应助slayers采纳,获得30
33秒前
量子星尘发布了新的文献求助10
36秒前
黑眼圈完成签到 ,获得积分10
42秒前
jia完成签到 ,获得积分10
43秒前
如履平川完成签到 ,获得积分10
44秒前
科目三应助忧伤的步美采纳,获得10
45秒前
大椒完成签到 ,获得积分10
48秒前
51秒前
53秒前
wisdom完成签到,获得积分10
53秒前
slayers发布了新的文献求助30
56秒前
57秒前
e746700020完成签到,获得积分10
58秒前
高兴尔冬完成签到,获得积分10
58秒前
李爱国应助不安的秋白采纳,获得10
1分钟前
忧伤的步美完成签到,获得积分10
1分钟前
小西完成签到 ,获得积分10
1分钟前
郝老头完成签到,获得积分10
1分钟前
13313完成签到,获得积分10
1分钟前
su完成签到 ,获得积分10
1分钟前
1分钟前
1分钟前
量子星尘发布了新的文献求助10
1分钟前
slayers完成签到 ,获得积分10
1分钟前
1分钟前
知犯何逆完成签到,获得积分10
1分钟前
Krsky完成签到,获得积分10
1分钟前
ding应助不安的秋白采纳,获得10
1分钟前
1分钟前
1分钟前
高分求助中
【提示信息,请勿应助】关于scihub 10000
Les Mantodea de Guyane: Insecta, Polyneoptera [The Mantids of French Guiana] 3000
徐淮辽南地区新元古代叠层石及生物地层 3000
The Mother of All Tableaux: Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 3000
Handbook of Industrial Diamonds.Vol2 1100
Global Eyelash Assessment scale (GEA) 1000
Picture Books with Same-sex Parented Families: Unintentional Censorship 550
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 4038039
求助须知:如何正确求助?哪些是违规求助? 3575756
关于积分的说明 11373782
捐赠科研通 3305574
什么是DOI,文献DOI怎么找? 1819239
邀请新用户注册赠送积分活动 892655
科研通“疑难数据库(出版商)”最低求助积分说明 815022